Illumina (NASDAQ:ILMN – Get Free Report) and VivoSim Labs (NASDAQ:VIVS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
89.4% of Illumina shares are held by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Comparatively, 1.0% of VivoSim Labs shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Illumina and VivoSim Labs’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Illumina | 18.36% | 29.84% | 12.17% |
| VivoSim Labs | -11,016.07% | -612.23% | -177.02% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Illumina and VivoSim Labs, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Illumina | 3 | 6 | 10 | 0 | 2.37 |
| VivoSim Labs | 1 | 0 | 0 | 0 | 1.00 |
Illumina currently has a consensus target price of $244.24, suggesting a potential upside of 2.44%. Given Illumina’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Illumina is more favorable than VivoSim Labs.
Volatility & Risk
Illumina has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, VivoSim Labs has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500.
Earnings & Valuation
This table compares Illumina and VivoSim Labs”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Illumina | $4.34 billion | 8.29 | $850.00 million | $5.81 | 41.04 |
| VivoSim Labs | $130,000.00 | 17.87 | -$13.84 million | ($4.47) | -0.03 |
Illumina has higher revenue and earnings than VivoSim Labs. VivoSim Labs is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.
Summary
Illumina beats VivoSim Labs on 12 of the 14 factors compared between the two stocks.
About Illumina
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
About VivoSim Labs
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
